Fundraising FoxGyldenpharma
Oxford, GB · 1 known investors
Find your way into Gyldenpharma
Sign up to see every warm intro you have to Gyldenpharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gyldenpharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gylden Pharma develops proprietary dermal delivery platforms for therapeutic medicines, using titanium microneedles and programmable gold nanoparticles to enable rapid, precise drug delivery through the skin. The company focuses on oncology and infectious disease applications including tumor immunotherapy and vaccine development.
Investors · 1
Vickers Venture Partnerslisted by Vickers Venture PartnersSingapore
How we know: the VCSheet dataset · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- GYLDEN PHARMA LIMITED
- Company number
- 09955881
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 18 Jan 2016
- Registered office
- 4 & 5 Dunmore Court Wootton Road, Abingdon, Oxfordshire, OX13 6BH
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- EMERGEX VACCINES HOLDING LIMITED (2016–2024)
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 7 Aug 2026 · next due 21 Aug 2027
Current officers · 8
- Dr Poh Hui Chia — director, appointed 5 Jan 2024
- Tony Flanagan — director, appointed 9 Jul 2026
- David Clifford Jackson — director, appointed 17 Aug 2022
- Fabricio Klerynton Marchini — director, appointed 27 Aug 2026
- Storme Jo-Anne Moore-Thornicroft — director, appointed 18 Jan 2016
- Thomas William Rademacher — director, appointed 18 Jan 2016
- Finian Tan Seng Chin — director, appointed 3 Sept 2019
- Frank Tufaro — director, appointed 17 Aug 2022
Source: Companies House public register · retrieved 13 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Gyldenpharma do?
- Gylden Pharma develops proprietary dermal delivery platforms for therapeutic medicines, using titanium microneedles and programmable gold nanoparticles to enable rapid, precise drug delivery through the skin. The company focuses on oncology and infectious disease applications including tumor immunotherapy and vaccine development.
- Who are Gyldenpharma's investors?
- Gyldenpharma's investors include Vickers Venture Partners.
- Where is Gyldenpharma headquartered?
- Gyldenpharma is headquartered in Oxford, GB.